Future work should address and quantify both the functionality of the NRF2 pathway in rhizomelic chondrodysplasia punctata and the AKT/GSK‐3β/NRF2 axis in other peroxisomal disorders, given the possibility of targeted treatments like DMF, for these metabolic diseases. The gene discussed is NFE2L2; the disease is rhizomelic chondrodysplasia punctata.